Bivalirudin half life

Prolonged half-life in patients with renal impairment. Avoid stasis If bivalirudin is not available, argatroban may also be considered.

The elimination half-life of bivalirudin is 20 to 30 min in the presence of normal renal function while with renal dysfunction, half-life can be prolonged

Bivalirudin is a synthetic direct thrombin inhibitor that is related to hirudin. The half-life of bi- valirudin is only 25 minutes, and it is predominantly.

Management of bleeding: - There is no reversal agent for bivalirudin, but it has a very short half-life (about 25 minutes in patients

bivalirudin has a short half-life. To date, bivalirudin is licensed for use only in percutaneous coronary interventions (PCI),8 and only a few published

Bivalirudin is a small peptide that inhibits thrombin reversibly. Bivalirudin is cleared by proteases including thrombin with approximately 80% elimination by enzymatic cleavage and the other 20% is renally eliminated. The elimination half-life of bivalirudin is 20 30 min in the presence of normal renal function.

ever, the half-life of bivalirudin is prolonged with severe renal impairment, and dose adjustments are needed. 17 Argatroban is predominantly cleared by hepatic

Excretion: Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage, with a half-life in patients with

Bivalirudin does not bind to plasma proteins (except thrombin) or to red blood cells. Elimination. Bivalirudin has a half-life of 25 minutes in PTCA patients with normal renal function. The total body clearance of bivalirudin in PTCA patients with normal renal function is 3.4 mL/min/kg. Metabolism. Bivalirudin is metabolized by proteolytic